Back Refine search Reset
Please choose a search criteria from below
Filters Clear all
Specialties
Treatments

83 results found in London

Sort by:
Showing 1 - 10 of 83 results
Oncology
Recommended by 3 specialists
18 years of experience
Medical Oncology

Dr Daniel Krell is a Consultant Oncologist, specialising in gastro-oesophageal, colorectal, pancreatic, liver and bile duct cancers and neuroendocrine tumours. He is experienced in using chemotherapy, targeted therapy and immunotherapy. Dr Krell also manages patients with cancer of unknown primary and is the clinical lead for this. He works as a member of the multidisciplinary team for gastro-oesophageal and hepatobiliary cancer at the Royal Free Trust. He is also the clinical lead for Neuroendocrine tumour oncology at The Royal Free Hospital.

He undertook oncology training at University College and the Royal Free Hospitals in London. In addition to his primary medical degree, he also gained a Bachelor’s degree in immunology and microbiology, in addition to a DPhil in Clinical Medicine at the University of Oxford’s Wellcome Trust Centre for Human Genetics and was funded by Cancer Research UK and HCA. His research involved the design of models to investigate the role that genetic mutations in genes controlling cellular metabolism play in the development of cancer. This may help identify new therapeutic targets in this area. Dr Krell continues to be involved in clinical research and trials aimed at identifying new cancer therapies, focused on gastrointestinal, hepatobiliary and neuroendocrine tumours. He has published a number of peer-reviewed papers and presented at national and international conferences.

Diseases, Medical Tests and Treatments

  • Chemotherapy
  • Immunotherapy
  • Biological Therapy
  • Genetic Testing
  • Liver Cancer
  • Biliary Cancer
  • Bowel Cancer
  • Colorectal Cancer
  • Oesophageal Cancer
  • Pancreatic Cancer
Read more
Oncology
23 years of experience
Medical Oncology

Dr Thomas Newsom-Davis a Consultant Medical Oncologist at Chelsea and Westminster Hospital. He specialises in thoracic malignancies, especially lung cancer and mesothelioma. In 2015, he was awarded the Macmillan Innovation Excellence Award.

Training

Dr Newsom-Davis completed his training at University College and Middlesex School of Medicine, London, in 1998, including First Class honours for his BSc. He went on specialise in medical oncology at Charing Cross and Hammersmith Hospitals and completed a PhD in tumour immunology. He was appointed to Chelsea & Westminster Hospital in 2010.

Current Roles

Dr Newsom-Davis leads the lung cancer service for Chelsea & Westminster Hospital, and is Vice Chair of the British Thoracic Oncology Group (BTOG) Steering Committee, an organistion which supports and educates thoracic oncology profressionals across the United Kingdom. Dr Newsom-Davis is Chair of the Harley Street Clinic lung cancer multidisciplinary team (MDT), and Chair of the HCA Healthcare UK Thoracic Oncology Board.

Research

Dr Newsom-Davis has an active clinical trial portfolio, and has presented his work at National and International meetings. He has been an invited lecturer for organisations including the Royal College of Physicians, European Society of Medical Oncology, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Diseases, Medical Tests and Treatments

  • Immunotherapy, Targeted Therapy, Chemotherapy
  • Lung Cancer
  • Mesothelioma
Read more
Oncology
Recommended by 1 specialist
29 years of experience
Medical Oncology

Dr Mulholland is a medical Oncologist who exclusively treats brain cancer at University College Hospital, the National Hospital for Neurology and Neurosurgery (part of UCLH) and Mount Vernon Cancer Centre.He is also an honorary senior lecturer at UCL and a training programme director. 

His doctoral research was in genomic profiling in brain cancer at Cancer Research UK - this has led to his focus on developing biomarkers and targets for therapy in brain cancer, including the clinical trial portfolio of novel agents in brain cancer which he now runs at UCLH and nationally. 

He is a clinical lead in a European Consortium called Datrix, a multidisciplinary European collaboration to advance next-generation targeted hyperthermic cancer treatment for glioblastoma.

 

 

 


Diseases, Medical Tests and Treatments

  • Cancer prevention and screening 
  • Chemotherapy 
  • Brain cancer 
  • Neuro-endocrine tumours 
  • Central nervous system cancer 
  • Novel agents 
Read more

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Read more

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Read more

Dr Jonathan Krell is a Consultant Oncologist specialising in breast and gynaecological cancers, with particular interest in cancer genetics and hereditary malignancies, especially with respect of BRCA and other gene mutations. His clinical focus is on the systemic management of patients with gynaecological and breast cancers. 

Dr Krell qualified in medicine at Leeds University Medical School, where he also gained a first class honours degree in Pharmacology. He completed junior doctor positions at St James’ Hospital, Leeds and St Thomas’ Hospitals in London. He then undertook oncology training at Charing Cross and Hammersmith Hospitals.

His PhD work was funded by the Medical Research Council and this investigated the interplay between genetic mutations, DNA damage and the response to cancer therapeutics. Dr Krell is a leading member of the translational research team within the Cancer Research UK and Ovarian Cancer Action centres at Imperial College that aim to overcome resistance to current anti-cancer agents in ovarian and breast cancer.

Dr Krell has published more than 100 peer-reviewed papers in academic journals and he regularly presents on his research at national and international conferences.

 


Diseases, Medical Tests and Treatments
  • Chemotherapy
  • Radiotherapy
  • Genetic Testing
  • Breast Cancer
  • Ovarian Cancer
  • Gynaecological Cancers

 

Read more

Dr Amen Sibtain is a Consultant Clinical Oncologist specialising in the management of Gastrointestinal, Hepatobiliary and Head and Neck cancers with chemotherapy and radiotherapy. He is also highly experienced in chemo-radiotherapy, state of the art radiotherapy techniques, including VMAT, stereotactic radiotherapy and radiosurgery, and intraoperative radiotherapy.

Dr Sibtain is presently the Clinical Director of GI oncology and Radiotherapy at St Bartholomew’s Hospital, an examiner in oncology for the Royal College of Radiologists, a member of the medical advisory panel for both Macmillan and CRUK, oncology advisor for BBC Drama and the Clinical Lead in Head and Neck Cancer at Barts. Dr Sibtain was previously President of the Oncology Section of the Royal Society of Medicine, Programme Director for Clinical Oncology Specialist Training Committee for the London Deanery and Chairman of the Head and Neck Tumour Board for North East London. He also previously worked at the Royal Marsden, Mount Vernon and The Middlesex Hospitals, before he took up his post at Barts. He was awarded an MD degree for his research in tumour hypoxia by the University of London.

As well as his clinical work he remains actively involved in research. He has been published in a number of peer-reviewed journals and edited the books Towards the Prevention of Cancer (2007) and Physics for Clinical Oncologists (2012).


Diseases, Medical Tests and Treatments

  • Chemotherapy
  • Cyberknife Therapy
  • Intensity Modulated Radiotherapy 
  • Radio Surgery
  • Radiotherapy
  • Rapid Arc
  • Stereotactic Radiotherapy 
  • Volumetric Arc Radiotherapy 
  • Anal Cancer
  • Bilary Cancer
  • Bowel Cancer  
  • Colon Cancer
  • Gastro-Intestinal Cancers
  • Head & Neck Cancers
  • Liver Cancer
  • Oesophageal Cancer
  • Pancreatic Cancer
  • Rectal Cancer
  • Stomach Cancer

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Read more
Oncology
22 years of experience
Clinical Oncology, Medical Oncology

Professor Tobias Arkenau is a renowned Consultant Medical Oncologist with HCA Healthcare at numerous locations including Sarah Cannon Research Institute, The Harley Street Clinic, The Princess Grace and The Wellington Hospital. Additionally, he holds an NHS post at University College London Hospital where he is a Professorial Research Associate.

He is a founding Medical Director of the Sarah Cannon Research Institute UK and is currently serving as the Executive Medical Director for SCRI UK and Clinical Lead for the HCA Healthcare UK Cancer Service Line. The talented physician has a wide range of experience in a variety of cancers, particularly gastrointestinal and skin cancers.

He was awarded his medical degree from Hanover Medical School in Germany in 2000. Following this, he completed his specialist training in oncology across numerous centres of excellence including the Royal Marsden Hospital. He was awarded a Fellowship by the Royal College of Physicians, and he is a key opinion leader in his field of Gastrointestinal Cancers, Drug Development and Immunotherapy for his reserach contributions to his field. During his career, he has published numerous peer reviewed articals and book chapters and contributes regulalry at international meetings such as ASCO, ESMO and AACR. He is leading the Sarah Cannon Institute UK as a Chief and Principal Investigator of numerous clinical trials of new anti-cancer drugs including immunotherapies and cellular therapies.

Diseases, Medical Tests and Treatments

  • Immunotherapy
  • Chemotherapy
  • Clinical Trials, Phase-1 studies
  • Drug Development, Experimental Therapies
  • TIL-Therapy
  • Biological Therapy
  • Video Consultation
  • Genetic Testing (Genomics Review Board)
  • Gastrointestinal Cancer
  • Skin Cancer
  • Upper Gastrointestinal Cancer
  • Lower Gastrointestinal Cancer
  • Melanoma
  • Bile Duct Cancer
  • Bowel Cancer
  • Colon Cancer
  • Gallbladder Cancer
  • Liver Cancer
  • Oesophagus Cancer
  • Pancreatic Cancer
  • Stomach Cancer
  • Small Bowel Cancer
Read more
Oncology
Recommended by 2 specialists
28 years of experience
Clinical Oncology, Medical Oncology

Dr Mary McCormack is a Consultant Clinical Oncologist, specialising in gynaecological andf breast cancers. She qualified in medicine from Guy's and St Thomas' Hospital. Before medical school, she undertook research in radiation biology and was awarded a PhD in 1989. Dr McCormack has worked in leading London cancer centres and in 2000, she was awarded the FRCR in clinical oncology. She was appointed a consultant at University College London Hospital in 2002.

Dr McCormack treats all subtypes of gynaecological cancer, including ovary, womb, uterus, cervix, vulva, vagina and also treats breast cancer. Treatments include chemotherapy, targeted/ biological therapy,radiotherapy and brachytherapy. She has a particular interest in cervical cancer treatment and targeted agents in breast, ovarian and endometrial cancer. Dr McCormack is a major contributor to national and international clinical trials and is the chief investigator on a nuber of studies. She is the current chair of the international Cervical Cancer Research Network (CCRN)and an exective member of the Gynaecologic Cancer Intergroup (GCIG)and a member of the International Gynaecologic Cancer Society's education committee.She is also a member of the ASCO International Affairs Committee.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.


Diseases, Medical Tests and Treatments
  • Radiotherapy
  • Chemotherapy
  • Brachytherapy
  • Cervical Cancer
  • Breast Cancer
  • Gynaecological Cancers
  • uterine cancer
  • vaginal and vulval cancer
  • ovary cancer
  • chemotherapy 
  • biological therapy
  • radiotherapy
Read more

Professor Peter Schmid is an internationally renowned breast cancer oncologist. He is the clinical director of the Breast Cancer Centre at St. Bartholomew’s Hospital in London, and Chair in Cancer Medicine at Barts Cancer Institute, Queen Mary University London. His private practice is based at LOC Harley Street, LOC at Chelsea, the Platinum Medical Centre, the Wellington Hospital, the Harley Street Clinic and at the Princess Grace Hospital.

Professor Schmid’s work is devoted to incorporating novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer. He has an interest in breast cancer from diagnosis throughout treatment to optimal recovery, and also has a particular interest in triple-negative breast cancer, young women with breast cancer, pregnancy-associated breast cancer and fertility related issues. Professor Schmid is committed to patient-centred, holistic care, tailoring treatments for individual patients using biology, personal preference and constant review of outcomes of care. He works in the context of a multidisciplinary team with breast care nurse support for patients. Professor Schmid has a strong interest in patient-doctor communication and ran a training programme for oncologists and oncology nurses for many years.

Professor Schmid’s research is dedicated to improving the care of women with breast cancer by developing more effective and less toxic treatments. He runs an international clinical and translational research programme. His group is investigating a variety of novel agents that target specific pathways within cancer cells and the surrounding tissue. He is the lead investigator of several international, pivotal breast cancer studies on novel targeted therapeutics to improve the treatment of both early and late stage breast cancer. Most trials incorporate translational research endpoints to improve our understanding of molecular factors that may elucidate mechanisms of action and predictors of treatment effect; this includes a programme on the impact of the microbiome on patient outcomes.  Professor Schmid is renowned internationally for his work in cancer immunotherapy. He was the lead investigator of the Impassion130 trial that evaluated atezolizumab for advanced triple-negative breast cancer and lead to the approval of the first immunotherapy strategy for patients with breast cancer, establishing a new standard of care for this disease. He was also the lead investigator of the KEYNOTE-522 trial which established the addition of the immune-checkpoint inhibitor Pembrolizumab to preoperative chemotherapy as a new standard for patients with stage II or III triple-negative breast cancer based on a nearly 40% reduction in recurrences of this aggressive subtype of breast cancer. His current research interests include cancer immune therapy combinations across all stages and subtypes of breast cancer, novel targeted agents and antibody-drug conjugates - alone or in combination - to overcome resistance, and innovative biomarker-driven trial concepts. Professor Schmid’s work has been published in many journals including the New England Journal of Medicine, Lancet, Lancet Oncology, JAMA Oncology, Nature Communications and the Journal of Clinical Oncology.

In addition to his clinical and research work, Professor Schmid is committed to education, regularly lecturing locally, nationally and internationally on subjects relating to the treatment of and supportive care for breast cancer. Professor Schmid is medical director of Perci Health, a virtual care clinic, to provide access to high-quality cancer experts across multi-disciplinary fields, focused holistically on recovery from a physical, mental, social and emotional point of view.

Prof Schmid is a member of several national and international cancer organisations and research groups. He has been involved in international consensus meetings on the management of breast cancer and is co-author of international breast cancer guidelines. Professor Peter Schmid is Chair of the European Society for Medical Oncology (ESMO) breast cancer faculty.

Areas of interest

  • Breast cancer from early breast cancer to advanced (secondary) disease, including endocrine treatment, immunotherapy, chemotherapy and targeted treatment.
  • Breast cancer in young adults
  • Triple-negative breast cancer
  • Interest in holistic management of side-effects of treatment, including aspects of fertility, pregnancy, menopausal symptoms and bone health.
  • Works in context of multidisciplinary team with breast care nurse support for patients.
  • Personalised medicines and appropriate genetic testing.
  • Immunotherapy
  • Novel targeted agents and antibody-drug conjugates
Read more